FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079532005> ?p ?o ?g. }

• W2079532005 endingPage "907" @default.
• W2079532005 startingPage "893" @default.
• W2079532005 abstract "Nonalcoholic fatty liver disease (NAFLD), first described in 1980, is now recognized as one of the most common causes of elevated liver enzymes and chronic liver disease in Western countries. The incidence of NAFLD in both adults and children is rising, in conjunction with the burgeoning epidemics of obesity and type 2 diabetes mellitus. NAFLD often coexists with other sequelae of the metabolic syndrome: central obesity, type 2 diabetes, hypertension, and hyperlipidemia. NAFLD encompasses a spectrum of pathologic liver diseases ranging from simple hepatic steatosis to a predominant lobular necro-inflammation, with or without centrilobular fibrosis (called nonalcoholic steatohepatitis or NASH). NASH can progress to cirrhosis, decompensated liver disease, and hepatocellular carcinoma. Though the natural history of NASH is still not clearly defined, it has been observed to progress to cirrhosis in 15%–220% of those affected. Insulin resistance is nearly universal in NASH and is thought to play an important role in its pathogenesis leading to dysregulated lipid metabolism. The prevalence of insulin resistance is reported in the general population to be approaching 45%, suggesting that NAFLD and NASH will contin nue to be an important public health concern. To date, NASH has proven to be a difficult disease to treat. Front-line therapy with lifestyle modifications resulting in weight loss through decreased caloric intake and moderate exercise is generally believed to be beneficial in patients with NASH, but is often difficult to maintain long term. Given that insulin resistance plays a dominant role in the pathogenesis, many studies have examined the use of insulin sensitizers: the biguanides (metformin), thiazolidinediones (pioglitazone, troglitazone, and rosiglitazone), glucagon-like peptide-1-receptor agonists, or incretins (exenatide)in NASH. This review will provide an overview of insulin resistance in NAFLD and provide a detailed summary on the clinical data regarding the use of insulin sensitizers in NASH." @default.
• W2079532005 created "2016-06-24" @default.
• W2079532005 creator A5052059601 @default.
• W2079532005 creator A5076502320 @default.
• W2079532005 creator A5091375453 @default.
• W2079532005 date "2009-10-01" @default.
• W2079532005 modified "2023-10-06" @default.
• W2079532005 title "Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status" @default.
• W2079532005 cites W1530129189 @default.
• W2079532005 cites W1896344567 @default.
• W2079532005 cites W1964209362 @default.
• W2079532005 cites W1964375545 @default.
• W2079532005 cites W1971698096 @default.
• W2079532005 cites W1977188464 @default.
• W2079532005 cites W1983890824 @default.
• W2079532005 cites W1984669204 @default.
• W2079532005 cites W1990055069 @default.
• W2079532005 cites W1991778481 @default.
• W2079532005 cites W1993063661 @default.
• W2079532005 cites W1996559225 @default.
• W2079532005 cites W1996641308 @default.
• W2079532005 cites W2001454915 @default.
• W2079532005 cites W2003945587 @default.
• W2079532005 cites W2006591225 @default.
• W2079532005 cites W2007516026 @default.
• W2079532005 cites W2013991546 @default.
• W2079532005 cites W2015643123 @default.
• W2079532005 cites W2017963081 @default.
• W2079532005 cites W2019280401 @default.
• W2079532005 cites W2028160831 @default.
• W2079532005 cites W2029811522 @default.
• W2079532005 cites W2038259293 @default.
• W2079532005 cites W2039800528 @default.
• W2079532005 cites W2042081120 @default.
• W2079532005 cites W2045107424 @default.
• W2079532005 cites W2045544544 @default.
• W2079532005 cites W2046360039 @default.
• W2079532005 cites W2049927985 @default.
• W2079532005 cites W2056505063 @default.
• W2079532005 cites W2056846940 @default.
• W2079532005 cites W2060963949 @default.
• W2079532005 cites W2064459152 @default.
• W2079532005 cites W2065788317 @default.
• W2079532005 cites W2070710390 @default.
• W2079532005 cites W2072390396 @default.
• W2079532005 cites W2075514437 @default.
• W2079532005 cites W2076733640 @default.
• W2079532005 cites W2077864706 @default.
• W2079532005 cites W2083896421 @default.
• W2079532005 cites W2100093159 @default.
• W2079532005 cites W2103156933 @default.
• W2079532005 cites W2106272645 @default.
• W2079532005 cites W2111951337 @default.
• W2079532005 cites W2118875360 @default.
• W2079532005 cites W2127125241 @default.
• W2079532005 cites W2138226825 @default.
• W2079532005 cites W2144178804 @default.
• W2079532005 cites W2155165300 @default.
• W2079532005 cites W2159171857 @default.
• W2079532005 cites W2162051951 @default.
• W2079532005 cites W2164118055 @default.
• W2079532005 cites W2166501811 @default.
• W2079532005 cites W2316193238 @default.
• W2079532005 cites W4376849750 @default.
• W2079532005 doi "https://doi.org/10.1007/s12325-009-0072-z" @default.
• W2079532005 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6659744" @default.
• W2079532005 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19921118" @default.
• W2079532005 hasPublicationYear "2009" @default.
• W2079532005 type Work @default.
• W2079532005 sameAs 2079532005 @default.
• W2079532005 citedByCount "78" @default.
• W2079532005 countsByYear W20795320052012 @default.
• W2079532005 countsByYear W20795320052013 @default.
• W2079532005 countsByYear W20795320052014 @default.
• W2079532005 countsByYear W20795320052015 @default.
• W2079532005 countsByYear W20795320052016 @default.
• W2079532005 countsByYear W20795320052017 @default.
• W2079532005 countsByYear W20795320052018 @default.
• W2079532005 countsByYear W20795320052020 @default.
• W2079532005 countsByYear W20795320052021 @default.
• W2079532005 countsByYear W20795320052022 @default.
• W2079532005 countsByYear W20795320052023 @default.
• W2079532005 crossrefType "journal-article" @default.
• W2079532005 hasAuthorship W2079532005A5052059601 @default.
• W2079532005 hasAuthorship W2079532005A5076502320 @default.
• W2079532005 hasAuthorship W2079532005A5091375453 @default.
• W2079532005 hasBestOaLocation W20795320052 @default.
• W2079532005 hasConcept C126322002 @default.
• W2079532005 hasConcept C134018914 @default.
• W2079532005 hasConcept C2776954865 @default.
• W2079532005 hasConcept C2777075537 @default.
• W2079532005 hasConcept C2777180221 @default.
• W2079532005 hasConcept C2777214474 @default.
• W2079532005 hasConcept C2777391703 @default.
• W2079532005 hasConcept C2778772119 @default.
• W2079532005 hasConcept C2779102576 @default.
• W2079532005 hasConcept C2779134260 @default.
• W2079532005 hasConcept C2779306644 @default.

• next